Q-omics provides the consensus-scored DBF4P3 profile across patient tissues and cancer cell-line models. DBF4P3 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, DBF4P3 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, DBF4P3 RNA expression shows 5,357 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight OV, THCA, and DLBC as cancer lineages where DBF4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DBF4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DBF4P3 survival associations across molecular data types. DBF4P3 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DBF4P3 RNA expression–survival associations across cancer types. High DBF4P3 expression shows unfavorable associations in OV, DLBC, COAD, UCEC, ACC and PAAD. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .026). Together, the overview and detailed table identify OV as the clearest survival context for DBF4P3 RNA expression.
This table summarizes DBF4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DBF4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DBF4P3 shows lower tumor expression in THCA. The THCA box plot shows higher DBF4P3 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p < 0.001).
This table shows molecular features associated with DBF4P3 in patient tissues and cancer cell lines. In patient samples, DBF4P3 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
